Table 1.
Patient and tumor characteristics
|
Characteristics |
Total patients |
|---|---|
| N (%) | |
|
No. |
212 |
|
Mean age (range)
|
63 (39-88) |
|
Diabetes Mellitus
|
23 (11%) |
|
Hypertension
|
25 (12%) |
|
Breast side
|
|
| Right |
110 (48%) |
| Left |
102 (52%) |
|
Breast Quadrant
|
|
| SE |
103 (48%) |
| SC |
38 (18%) |
| II |
12 (6%) |
| IE |
17 (8%) |
| IC |
11 (5%) |
| CE |
8 (4%) |
| SI |
23 (11%) |
|
Histological type
|
|
| IDC |
152 (72%) |
| ILC |
17 (8%) |
| Intraductal |
41 (19%) |
| Other |
1 (1%) |
|
T stage
|
|
| T0 |
3 (2%) |
| T is |
41 (19%) |
| T 1a |
11 (5%) |
| T 1b |
43 (20%) |
| T 1c |
82 (39%) |
| T 2 |
32 (15%) |
|
N stage
|
|
| Nx |
13 (6%) |
| N0 |
165 (78%) |
| N1 |
34 (16%) |
|
Grading
|
|
| G1 |
32 (15%) |
| G2 |
118 (56%) |
| G3 |
56 (26%) |
| NA |
6 (3%) |
|
Surgical margins
|
|
| Negative |
186 (82%) |
| Positive |
5 (2%) |
| Close (< 2 mm) |
19 (9%) |
| NA |
1 (1%) |
|
Chemotherapy
|
|
| Yes |
44 (21%) |
| (Neoadjuvant) |
10 |
| (Adjuvant) |
34 |
| No |
167 (79%) |
|
Hormone therapy
|
|
| Yes |
159 (75%) |
| No |
42 (20%) |
| NA |
11 (5%) |
|
Trastuzumab
|
|
| Yes |
18 (8%) |
| No | 194 (92%) |
IDC – infiltrating ductal carcinoma; ILC – infiltrating lobular carcinoma; NA - not applicable; SE – supero-interne; II – infero-interne; SE – supero-externe; IE – infero-externe; SC – supero-central; IC – infero-central; SI – supero-interne; CE - central.